![Milbank LLP [Freddy Pilkington]](https://www.milbank.com/a/web/wzohrx8ErczQV5vkN6GCY1/91Hxdu/pilkington-freddy-lon-web.jpg "Milbank LLP [Freddy Pilkington]")
Milbank LLP has advised Investindustrial on the acquisition of DCC’s healthcare division.
DCC Healthcare is an independently run division of DCC plc (an Irish-incorporated, UK-listed company), and is active across healthcare markets that are supported by enduring megatrends, including a focus on wellbeing, increasing ageing population and a growing need for care. The acquisition of DCC Healthcare allows Investindustrial to leverage its strong track record and expertise in the food supplement CDMO and medical devices verticals.
The acquisition values DCC Healthcare at a total enterprise value of £1,050 million on a cash-free, debt-free basis. The transaction is subject to receipt of customary regulatory approvals and is expected to complete in the third quarter of 2025.
The Milbank team was led by partners James McClymont and Jordan Simpson (Corporate/Private Equity).
Paul Buchan (partner, Corporate/Private Equity) handled M&A aspects, alongside associates Michael Terry, Daniel Carolan, Catriona Mather and Lucy Reville, and trainees Annis Easton and Charlie Thomas.
Andrew Nuthall (partner, Corporate/Private Equity) addressed carve-out and separation issues, with support from associate Hannah Gong (Corporate/Private Equity).
Specialist input was provided by partners Ajal Notowicz (Antitrust and FDI) and Alan Rafferty (Tax), and associate Freddy Pilkington (Tax).
